| 坎地沙坦酯联合氢氯噻嗪治疗中重度高血压的临床疗效比较 |
| |
| 引用本文： | 汪庆飞,高家荣,张配. 坎地沙坦酯联合氢氯噻嗪治疗中重度高血压的临床疗效比较[J]. 中华全科医学, 2019, 17(7): 1132-1134. DOI: 10.16766/j.cnki.issn.1674-4152.000882 |
| |
| 作者姓名： | 汪庆飞 高家荣 张配 |
| |
| 作者单位： | 1. 蚌埠医学院第二附属医院药剂科, 安徽 蚌埠 233040; |
| |
| 基金项目： | 国家自然科学基金项目(81603155) |
| |
| 摘 要： | 目的分析中重度高血压应用坎地沙坦酯或贝那普利与氢氯噻嗪联合治疗的临床疗效情况。方法选择蚌埠医学院第二附属医院2016年6月-2018年7月诊治的86例高血压患者,按照随机数字表分成研究组(43例)与对照组(43例),对照组使用贝那普利(规格:10 mg*10片,开始剂量为每次5 mg,每日1次)联合氢氯噻嗪(规格:25 mg*100片,开始剂量为每次25 mg,每日1次)治疗,研究组予以坎地沙坦酯(规格:4 mg*14片,起始剂量每日1次,每次8 mg)结合氢氯噻嗪治疗,观察并比较2组患者血压、血钾与肾功能、不良反应情况。结果治疗前,2组血压指标差异无统计学意义(P>0.05);治疗后,2组舒张压、收缩压均有改善(P<0.05),且研究组舒张压(77.42±8.53)mm Hg、收缩压(121.31±15.84) mm Hg等血压指标改善情况显著优于对照组(P<0.05);研究组尿酸水平为(368.46±98.79)μmol/L,低于对照组的(412.36±102.14)μmol/L,差异有统计学意义(P<0.05),研究组出现低血钾症、头痛等不良反应的概率(6.98%)明显低于对照组(23.26%),比较差异具有统计学意义(P<0.05)。结论与贝那普利结合氢氯噻嗪相比,坎地沙坦酯与氢氯噻嗪结合应用对中重度高血压的疗效更佳,可明显控制血压水平,保护肾功能,且不良反应少。
|
| 关 键 词： | 贝那普利 坎地沙坦酯 氢氯噻嗪 血清肌酸酐 疗效 |
| 收稿时间： | 2018-11-25 |
Clinical efficacy of candesartan combined with hydrochlorothiazide for moderate to severe hypertension |
| |
| WANG Qing-fei,GAO Jia-rong,ZHANG Pei. Clinical efficacy of candesartan combined with hydrochlorothiazide for moderate to severe hypertension[J]. Applied Journal Of General Practice, 2019, 17(7): 1132-1134. DOI: 10.16766/j.cnki.issn.1674-4152.000882 |
| |
| Authors: | WANG Qing-fei GAO Jia-rong ZHANG Pei |
| |
| Affiliation: | Department of Pharmacy, the Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233040, China |
| |
| Abstract: | Objective To analyze the effects of Candesartan or Benazepril combined with Hydrochlorothiazide in the treatment of moderate to severe hypertension. Methods Eighty-six patients with moderate to hypertension who were treated in the Second Affiliated Hospital of Bengbu Medical College between June 2016 and July 2018 were enrolled in the study, and were randomly divided into a study group (n=43) and a control group (n=43) according to the random number table. The control group was treated with Benazepril (Specification: 10 mg*10 s, starting dose of 5mg each time, once a day) combined with Hydrochlorothiazide (Specification: 25 mg*100 s, once a day, 25 mg each time). The study group was given Dexartan (Specification: 4 mg*14 tablets, once a day, 8 mg each time) combined with Hydrochlorothiazide for treatment. The blood pressure, blood potassium and renal function, and adverse reactions were observed and compared between the two groups. Results Before treatment, there was no significant difference in blood pressure between the two groups (P>0.05). After treatment, both diastolic blood pressure and systolic blood pressure were improved in the two groups(P<0.05), with the diastolic blood pressure and systolic blood pressure in the study group, which were(77.42±8.53) mm Hg and (121.31±15.84) mm Hg, significantly better than the control group (P<0.05). The level of uric acid in the study group was (368.46±98.79) μmol/L, lower than that in the control group, which was (412.36±102.14) μmol/L, and the difference was statistically significant (P<0.05). The incidence of adverse reactions such as hypokalemia and headache in the study group was 6.98%, significantly lower than that in the control group, which was 23.26%, and the difference was statistically significant (P<0.05). Conclusion Compared with Benazepril combined with Hydrochlorothiazide, Candesartan combined with Hydrochlorothiazide is more effective in the treatment of moderate to severe hypertension, which can significantly control the blood pressure level, protect renal function, and yet incur less adverse reactions. |
| |
| Keywords: | Benazepril Candesartan Hydrochlorothiazide Serum Creatinine Efficacy |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载免费的PDF全文 |
|
